Healthpeak's Life Science Pendulum Swings Back: From Downturn to Acquisition Game
Occupancy inflecting, capital markets reopening, and management pivots to opportunistic acquisitions while JVs fund growth.
DOC · Earnings Call · 2026-08-05
The Corner Turns
Investors dialing into Healthpeak's Q2 2026 call heard a very different tone from the prior year. The life science downturn that had dragged occupancy down for four years is now showing consistent signs of inflection. The company reported total life science occupancy up 80 basis points sequentially to 78.5%, a 140 basis point improvement since year-end 2025, and pointed to a leasing pipeline that continues to convert at an improving pace. CEO Scott Brinker framed the moment bluntly:
Life science has been a development game for the past decade, for the next few years, it will be an acquisition game, and we have the platform and balance sheet to capitalize on the opportunity.
This is a strategic pivot, not just an operational recovery. Management explicitly shifts from a period of defensive balance sheet management to offensive capital deployment, funded by recent joint ventures with Blackstone and Brookfield that bring alternative equity capital while retaining Healthpeak as the operating partner.
Lab Occupancy: From Slide to Swing
The driver of the turnaround is the lab portfolio. Kelvin Moses, CIO, detailed 381,000 square feet of leases executed in the quarter, with roughly 60% new leasing and 30% on vacant space. Since July 1, the company has signed another 20,000 square feet, with 480,000 square feet under LOI. The highlight is Torrey Pines, where executed leases plus LOIs push the submarket occupancy to 97%, up from ~65% at year-end 2025. As Scott Brinker noted, "same store is less relevant"—the real focus is total occupancy and NOI growth: “The real key is total occupancy and moving NOI in that segment higher. That is what generates earnings growth and ultimately share price.” — Scott Brinker, President and Chief Executive Officer · 2026-08-05 This emphasis on total occupancy over same-store metrics is a notable management philosophy shift, aligning with the acquisition-led strategy.
Pivot to Opportunistic Acquisitions
The call was notable for how much airtime was spent on capital allocation rather than just leasing. The Brookfield JV, completed in the quarter, raised $1.0 billion in proceeds at a 5.9% trailing cap rate while retaining 51% ownership and full management control. This followed the earlier Blackstone partnership. Scott Brinker framed the opportunity: “The building blocks for the sector recovery are definitely there. And we are starting to translate that into leasing pipeline and leasing growing occupancy. So things are definitely getting better.” — Scott Brinker, President and Chief Executive Officer · 2026-08-05 The pivot to opportunistic life science acquisitions is well supported by the balance sheet: net debt to adjusted EBITDA is 4.7x, and the company raised full-year FFO guidance by $0.02 to $1.73–$1.77.
Financial Inflection
The earnings inflection is visible in the fundamentals. Net income swung to $200M in Q2 2026, up 299% year-over-year, as the occupancy recovery began to flow through. $200M net income, up 299% YoY Interest expense, however, rose 20% YoY, reflecting higher refinancing costs, but the company's leverage remains manageable. The guidance raise reflects not only lab occupancy improvements but also a 200 basis point increase in senior housing same-store NOI, driven by Janus Living's strong performance.
Contrast with Prior Quarters
The shift in messaging is stark compared to prior calls. Just three months ago, management was still cautious, emphasizing headwinds and the need to "manage debt maturities" and "maintain flexibility." In the May 2026 call, Scott Brinker said, “the pipeline is building, it's broad-based from biotech to pharma and wet lab and everything in between with continued strong leasing economics.” — Scott Brinker, President and Chief Executive Officer · 2026-05-06 Now they are talking about deploying capital into acquisitions and joint ventures. This is a classic case of a REIT transitioning from defensive to offensive mode, and the market is rewarding it—the stock is up 27.8% over the past 90 days.
The modest improvement in total occupancy is no longer just a hope but a trend that management expects to accelerate into 2027. With the balance sheet at its strongest point in years, Healthpeak is positioning itself as a consolidator in a recovering life science market, backed by transformative partnerships that supply capital without diluting the landlord's control.